Twist Bioscience reported an 18% revenue increase in fiscal Q3 2025, driven by 27% growth in next-generation sequencing and 7% in synthetic biology. The company shipped approximately 237,000 genes, expanding its healthcare and academic customer base. Following the earnings beat, Twist narrowed its full-year 2025 revenue guidance to $374–376 million. This performance signals robust demand for synthetic biology and sequencing products, underpinning the firm’s growth amid evolving scientific and therapeutic discovery landscapes.